The IDWeek 2022 took place live from October 19-23 in Washington. Once again this year, the ‘late breaker abstracts’ sessions offered a range of current and interesting topics. For example, attention was paid to age as the most important risk factor for serious COVID-19 in vaccinees and to the important role of sabizabulin in the reduction of COVID-19 mortality. In addition, letermovir has been shown to be effective in the prevention of cytomegalovirus (CMV) in high-risk renal transplant recipients and ceftobiprole is non-inferior to daptomycin in the treatment of S aureus bacteremia. Also: telehealth is not really gaining a foothold in HIV care, long-acting cabotegravir + rilpivirine and fewer exacerbations in chronic rhinosinusitis thanks to a new device.
More information is only accessible to subscribers who have prescribing authority.
Login